Want to see ALKS full AI Analyst Report?
ALKS Stock Chart & Stats
$52.89
-$0.16(-0.30%)
At close: 4:00 PM EDT
$52.89
-$0.16(-0.30%)
Day’s Range― - ―
52-Week Range$25.17 - $55.67
Previous Close$52.51
Volume1.40M
Average Volume (3M)2.23M
Market Cap
$8.29B
Enterprise Value$10.01K
Total Cash (Recent Filing)$656.58M
Total Debt (Recent Filing)$1.57B
Price to Earnings (P/E)122.6
Beta0.70
Next Earnings
Oct 28, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.40
Shares Outstanding167,763,280
10 Day Avg. Volume1,520,631
30 Day Avg. Volume2,234,059
Financial Highlights & Ratios
PEG Ratio-0.56
Price to Book (P/B)2.53
Price to Sales (P/S)3.12
P/FCF Ratio9.59
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$58.25Price Target Upside10.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)-0.48
Revenue Forecast (FY)$1.82B
Bulls Say, Bears Say
Bulls Say
Proprietary Product Sales GrowthSustained proprietary sales growth (+34% YoY) indicates durable commercial momentum across multiple franchises. That expands recurring, higher-margin revenue, supports scale for marketing and access investments, and reduces short-term reliance on volatile partner manufacturing revenues.
Strong Cash GenerationConsistent positive operating and free cash flow with sizable cash-like resources underpins financial flexibility. This durable cash generation funds R&D and integration costs, services debt, and provides a buffer against execution risk while the pipeline and new products scale.
Orexin Pipeline And Regulatory IncentivesOrphan designation plus active Phase 3 programs provide structural upside: potential extended exclusivity and development incentives can improve commercial positioning in rare sleep disorders, supporting long-term revenue optionality and differentiation versus competitors.
Bears Say
Rising LeverageA sudden jump in leverage to ~0.87 materially reduces financial flexibility and heightens sensitivity to interest costs and covenants. This constrains capital allocation, increases refinancing risk, and can limit ability to opportunistically fund pipeline investments or M&A without further dilution.
Profitability DeteriorationNet margin compression to ~4% from prior stronger levels signals weaker earnings durability. Lower profitability reduces retained cash for reinvestment, worsens returns on equity, and makes the business more vulnerable to revenue swings and pricing pressure over the medium term.
Higher Operating Costs & GTN PressureExpanding gross-to-net, rising R&D and SG&A from acquisition integration, and contingent consideration charges structurally compress margins. Elevated fixed and variable costs increase the revenue required to sustain profits and heighten execution risk while the orexin franchise and LUMRYZ scale.
Alkermes News
ALKS FAQ
What was Alkermes’s price range in the past 12 months?
Alkermes lowest stock price was $25.16 and its highest was $55.67 in the past 12 months.
What is Alkermes’s market cap?
Alkermes’s market cap is $8.29B.
When is Alkermes’s upcoming earnings report date?
Alkermes’s upcoming earnings report date is Oct 28, 2026 which is in 77 days.
How were Alkermes’s earnings last quarter?
Alkermes released its earnings results on Jul 28, 2026. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.027 by $0.027.
Is Alkermes overvalued?
According to Wall Street analysts Alkermes’s price is currently Undervalued.
Does Alkermes pay dividends?
Alkermes does not currently pay dividends.
What is Alkermes’s EPS estimate?
Alkermes’s EPS estimate is -0.04.
How many shares outstanding does Alkermes have?
Alkermes has 167,763,280 shares outstanding.
What happened to Alkermes’s price movement after its last earnings report?
Alkermes reported an EPS of $0 in its last earnings report, beating expectations of -$0.027. Following the earnings report the stock price went down -4.229%.
Which hedge fund is a major shareholder of Alkermes?
Currently, no hedge funds are holding shares in ALKS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alkermes Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$58.25 (10.13% Upside)
$58.25 (10.13% Upside)
Blogger Sentiment
Bullish
ALKS Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 240.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 7.7%
Last 30 Days ▼ 7.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
99.35%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
95.01%
Trailing 12-Months
Company Description
Alkermes
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
ALKS Company Deck
ALKS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and meaningful clinical progress, particularly across the orexin franchise and the successful integration of Avadel/LUMRYZ. Key revenue and access wins (proprietary sales +34% YoY, LYBALVI access >80%, LUMRYZ patient growth +25% YoY) and robust pipeline readouts (alixorexton LTE durability, Positive LUMRYZ Phase 3, multiple orexin programs advancing) underpin optimism. Offsetting items include margin pressure from expanding gross-to-net (LYBALVI), a substantial increase in R&D and SG&A tied to pipeline advancement and acquisition integration, a contingent consideration charge that pushes the GAAP loss guidance negative, and competitive/pricing uncertainty from other orexin entrants. Overall, the positive commercial and clinical developments outweigh the cost and near-term margin headwinds.View all ALKS earnings summariesALKS Revenue Breakdown
89.69% U.S.
10.24% Rest of world
0.07% Ireland
ALKS Stock 12 Month Forecast
Average Price Target
$58.25
▲(10.13% Upside)
Technical Analysis
Ownership Overview
1.41% Insiders
25.97% Mutual Funds
3.03% Other Institutional Investors
38.52% Public Companies and
Individual Investors